Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report)’s share price traded up 11% during trading on Tuesday. The company traded as high as C$0.46 and last traded at C$0.46. Approximately 236,408 shares traded hands during mid-day trading, an increase of 174% from the average session volume of 86,229 shares. The stock had previously closed at C$0.41.
Medicenna Therapeutics Price Performance
The stock’s 50-day simple moving average is C$0.42 and its two-hundred day simple moving average is C$0.47. The company has a market capitalization of C$41.53 million, a price-to-earnings ratio of -2.05 and a beta of 2.93. The company has a quick ratio of 4.65, a current ratio of 1.25 and a debt-to-equity ratio of 6.22.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.
Further Reading
- Five stocks we like better than Medicenna Therapeutics
- Only 20 Stocks Are Holding Up the Market: 3 Bargains Outside AI
- Front-Running the AI Hardware Shift with Cerebras
- BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to Change
- Constellation Brands Beat Earnings, But Beer Demand Is Still a Problem
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
